Journal of Medicinal Chemistry · 2006 · 78 citations · 29 references
Veterinary MedicineMedicinal ChemistryPharmacologyMolecular PharmacologyPrion DiseasesStructure-activity RelationshipsEnzyme InhibitionPrion Protein MisfoldingPrion Protein StructurePrion ReplicationStructure-activity Relationship AnalysisAntimalarial AgentsAntimalarial Drug DevelopmentCellular Prion PropagationCellular Prion Protein StructureHalf-maximal Inhibitory ConcentrationPharmacological PotencyQuinoline Chemistry
Prion diseases are invariably fatal neurodegenerative diseases, in which the infectious agent consists of PrP(Sc), a pathogenic misfolded isoform of the normal cellular prion protein (PrP(C)). Until now, no pharmacological options exist for these novel pathogens. Here we describe the screening of a series of polyquinolines and quinolines linked to a large variety of terminal groups for their ability to cure a persistently prion infected cell line (ScN2a). Several compounds showed antiprion activity in the nanomolar range. The most active molecule, named 42, had a half-effective concentration (EC50) for antiprion activity of 50 nM. In a library of quinoline derivatives we were able to identify several structure-activity relationships (SAR). Remarkably, antiprion SAR in ScN2a cells were similar to antimalarial SAR in a cell model of malaria, particularly for the sulfonamide quinoline derivatives, suggesting that some molecular targets of antiprion and antimalarial substances overlap.
29
Human Malaria Parasites in Continuous Culture
William Trager, James B. Jensen · Science · 1976 · 8K citations
Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD
John Collinge, Katie Sidle, Julie Meads et al. · Nature · 1996 · 1.7K citations
Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion
C. A. Llewelyn, P. B Hewitt, RSG Knight et al. · The Lancet · 2004 · 1.1K citations